Sugar-Free Actiq "Approvable" Pending Chemistry, Manufacturing Clearance
This article was originally published in The Pink Sheet Daily
Cephalon describes outstanding issues as "technical" in nature and expects final approval within six months. The sugar-free formulation was developed in response to post-marketing reports of dental cavities, the company says.
You may also be interested in...
Cephalon is planning to launch an in-house generic version of Actiq (transmucosal fentanyl) to compete with Barr, the company said
Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter